Walleye Capital LLC Sells 141,324 Shares of iCAD, Inc. (NASDAQ:ICAD)

Walleye Capital LLC lessened its position in shares of iCAD, Inc. (NASDAQ:ICADGet Rating) by 77.1% in the second quarter, HoldingsChannel reports. The fund owned 41,891 shares of the technology company’s stock after selling 141,324 shares during the period. Walleye Capital LLC’s holdings in iCAD were worth $168,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ICAD. Essex Investment Management Co. LLC boosted its holdings in shares of iCAD by 4.8% during the first quarter. Essex Investment Management Co. LLC now owns 122,011 shares of the technology company’s stock worth $544,000 after acquiring an additional 5,639 shares during the period. Greenwood Capital Associates LLC boosted its holdings in shares of iCAD by 44.4% during the first quarter. Greenwood Capital Associates LLC now owns 226,593 shares of the technology company’s stock worth $1,011,000 after acquiring an additional 69,704 shares during the period. Country Club Bank GFN bought a new stake in shares of iCAD during the first quarter worth approximately $53,000. Raymond James & Associates boosted its holdings in shares of iCAD by 62.1% during the first quarter. Raymond James & Associates now owns 21,750 shares of the technology company’s stock worth $97,000 after acquiring an additional 8,331 shares during the period. Finally, Granite Point Capital Management L.P. raised its position in shares of iCAD by 69.1% in the first quarter. Granite Point Capital Management L.P. now owns 126,858 shares of the technology company’s stock valued at $566,000 after buying an additional 51,858 shares in the last quarter. Institutional investors own 52.68% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Craig Hallum dropped their price target on shares of iCAD to $6.00 in a research report on Monday, August 15th. Lake Street Capital dropped their price target on shares of iCAD from $8.00 to $5.00 in a research report on Friday, November 11th. BTIG Research dropped their price target on shares of iCAD to $4.00 in a research report on Wednesday. StockNews.com assumed coverage on shares of iCAD in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, JMP Securities dropped their price target on shares of iCAD from $13.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, September 1st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.60.

iCAD Price Performance

Shares of ICAD opened at $1.91 on Friday. iCAD, Inc. has a one year low of $1.61 and a one year high of $8.61. The company has a market cap of $48.38 million, a P/E ratio of -3.29 and a beta of 1.17. The firm has a 50 day simple moving average of $2.07 and a two-hundred day simple moving average of $3.14.

Insider Buying and Selling at iCAD

In other iCAD news, CTO Jonathan Go sold 38,960 shares of the business’s stock in a transaction that occurred on Monday, September 12th. The shares were sold at an average price of $2.74, for a total transaction of $106,750.40. Following the completion of the transaction, the chief technology officer now directly owns 188,725 shares in the company, valued at $517,106.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 12.50% of the company’s stock.

iCAD Profile

(Get Rating)

iCAD, Inc is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products.

Read More

Want to see what other hedge funds are holding ICAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iCAD, Inc. (NASDAQ:ICADGet Rating).

Institutional Ownership by Quarter for iCAD (NASDAQ:ICAD)

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.